1 From the Laboratory of Pathological Anatomy, University of Amsterdam, The Netherlands.
Morphologic and morphometric studies were carried out on pulmonary vessels in lung tissue from 156 patients, for whom a diagnosis of primary pulmonary hypertension had been made. This material was collected from 51 medical centers. Chronic pulmonary thromboembolism can be recognized by organizing thrombi, patchy intimal fibrosis, and intra-arterial septa. The media is only slightly thicker than normal; in 31 of the 156 cases the vascular lesions corresponded to this pattern. Other conditions such as chronic pulmonary venous hypertension, pulmonary veno-occlusive disease, sarcoidosis, chronic bronchitis, and pulmonary schistosomiasis could also be classified from the morphologic criteria. The largest group comprised 110 cases showing medial hypertrophy, laminar intimal fibrosis, and often fibrinoid necrosis, arteritis, and plexiform lesions. These alterations suggest that they were initiated by vasoconstriction. In children the sex ratio is equal; in adults there are almost four females to one male. In these patients with vasoconstrictive primary pulmonary hypertension, various stimuli are likely to bring about vasoconstriction in the presence of a pronounced pulmonary vascular hyperreactivity. A review of 602 cases from the literature is given.
Submitted on June 4, 1970
© 1970 American Heart Association, Inc.
Primary Pulmonary Hypertension
A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases
Key Words: Pulmonary vascular lesions • Laminar intimal fibrosis • Patchy intimal fibrosis • Plexiform lesions • Pulmonary vasoconstriction • Etiology • Pulmonary vascular hyperreactivity • Chronic pulmonary thromboembolism • Raynaud's phenomenon • Intimal and medial hypertrophy
Accepted on August 20, 1970
This article has been cited by other articles:
 |
|
 |
|
  M. Li, L. Kuo, and J. N. Stallone Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2444 - H2455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Klinger Pulmonary Arterial Hypertension: An Overview Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 96 - 103. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Sakao, L. Taraseviciene-Stewart, K. Wood, C. D. Cool, and N. F. Voelkel Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth Am J Physiol Lung Cell Mol Physiol, September 1, 2006; 291(3): L362 - L368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guignabert, M. Izikki, L. I. Tu, Z. Li, P. Zadigue, A.-M. Barlier-Mur, N. Hanoun, D. Rodman, M. Hamon, S. Adnot, et al. Transgenic Mice Overexpressing the 5-Hydroxytryptamine Transporter Gene in Smooth Muscle Develop Pulmonary Hypertension Circ. Res., May 26, 2006; 98(10): 1323 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Newman Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1072 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Li and J. N. Stallone Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1542 - H1550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guignabert, B. Raffestin, R. Benferhat, W. Raoul, P. Zadigue, D. Rideau, M. Hamon, S. Adnot, and S. Eddahibi Serotonin Transporter Inhibition Prevents and Reverses Monocrotaline-Induced Pulmonary Hypertension in Rats Circulation, May 31, 2005; 111(21): 2812 - 2819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ono, Y. Sawa, N. Fukushima, H. Suhara, T. Nakamura, C. Yokoyama, T. Tanabe, and H. Matsuda Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats Eur. J. Cardiothorac. Surg., December 1, 2004; 26(6): 1092 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ono, Y. Sawa, S. Mizuno, N. Fukushima, H. Ichikawa, K. Bessho, T. Nakamura, and H. Matsuda Hepatocyte Growth Factor Suppresses Vascular Medial Hyperplasia and Matrix Accumulation in Advanced Pulmonary Hypertension of Rats Circulation, November 2, 2004; 110(18): 2896 - 2902. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Damas, K. Otterdal, A. Yndestad, H. Aass, N. O. Solum, S. S. Froland, S. Simonsen, P. Aukrust, and A. K. Andreassen Soluble CD40 Ligand in Pulmonary Arterial Hypertension: Possible Pathogenic Role of the Interaction Between Platelets and Endothelial Cells Circulation, August 24, 2004; 110(8): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin Introduction: Diagnosis and Management of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 7S - 10S. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension Chest, February 1, 2004; 125(2): 580 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marcos, S. Adnot, M. H. Pham, A. Nosjean, B. Raffestin, M. Hamon, and S. Eddahibi Serotonin Transporter Inhibitors Protect against Hypoxic Pulmonary Hypertension Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 487 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Rodes-Cabau, E Domingo, A Roman, J Majo, B Lara, F Padilla, I Anivarro, J Angel, J C Tardif, and J Soler-Soler Intravascular ultrasound of the elastic pulmonary arteries: a new approach for the evaluation of primary pulmonary hypertension Heart, March 1, 2003; 89(3): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Widlitz and R.J. Barst Pulmonary arterial hypertension in children Eur. Respir. J., January 1, 2003; 21(1): 155 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eddahibi, N. Morrell, M-P. d'Ortho, R. Naeije, and S. Adnot Pathobiology of pulmonary arterial hypertension Eur. Respir. J., December 1, 2002; 20(6): 1559 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Shitrit, D. Bendayan, A. Bar-Gil-Shitrit, M. Huerta, B. Rudensky, G. Fink, and M. R. Kramer Significance of a Plasma D-dimer Test in Patients With Primary Pulmonary Hypertension Chest, November 1, 2002; 122(5): 1674 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Fulton and J. N. Stallone Sexual dimorphism in prostanoid-potentiated vascular contraction: roles of endothelium and ovarian steroids Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H2062 - H2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.M. Hoeper Pulmonary hypertension in collagen vascular disease Eur. Respir. J., March 1, 2002; 19(3): 571 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Walker, J. Loscalzo, and Y.-Y. Zhang 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation Am J Physiol Heart Circ Physiol, February 1, 2002; 282(2): H585 - H593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Robbins, R. J. Barst, L. J. Rubin, S. P. Gaine, P. V. Price, J. D. Morrow, and B. W. Christman Increased Levels of Prostaglandin D2 Suggest Macrophage Activation in Patients With Primary Pulmonary Hypertension Chest, November 1, 2001; 120(5): 1639 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J McMahon, J Kadkin, and M R Nihill Rapid regression of primary pulmonary hypertension Heart, July 1, 2001; 86(1): e1 - 1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. TARASEVICIENE-STEWART, Y. KASAHARA, L. ALGER, P. HIRTH, G. MC MAHON, J. WALTENBERGER, N. F. VOELKEL, and R. M. TUDER Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension FASEB J, February 1, 2001; 15(2): 427 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P S C Wong, S Constantinides, V Kanellopoulos, C R Kennedy, D Watson, and M F Shiu Primary pulmonary hypertension in pregnancy J R Soc Med, January 10, 2001; 94(10): 523 - 525. [Full Text] [PDF]
|
|
|
|
|
|
S. Machherndl, M. Kneussl, H. Baumgartner, B. Schneider, V. Petkov, P. Schenk, and I.M. Lang Long-term treatment of pulmonary hypertension with aerosolized iloprost Eur. Respir. J., January 1, 2001; 17(1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sakamaki, S. Kyotani, N. Nagaya, N. Sato, H. Oya, T. Satoh, and N. Nakanishi Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy Circulation, November 28, 2000; 102(22): 2720 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. MANDEL, E. J. MARK, and C. A. HALES Pulmonary Veno-occlusive Disease Am. J. Respir. Crit. Care Med., November 1, 2000; 162(5): 1964 - 1973. [Full Text]
|
|
|
|
|
|
R Ziesche, V Petkov, K Wittmann, J Kopatschka, L Stiebellehner, P Schenk, P Germann, G Röder, R Ullrich, and L H Block Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension Heart, April 1, 2000; 83(4): 406 - 409. [Abstract] [Full Text]
|
|
|
|
|
|
I. M. Robbins, S. P. Gaine, R. Schilz, V. F. Tapson, L. J. Rubin, and J. E. Loyd Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus Erythematosus* Chest, January 1, 2000; 117(1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Veyssier-Belot and P. Cacoub Role of endothelial and smooth muscle cells in the physiopathology and treatment management of pulmonary hypertension Cardiovasc Res, November 1, 1999; 44(2): 274 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Cool, J. S. Stewart, P. Werahera, G. J. Miller, R. L. Williams, N. F. Voelkel, and R. M. Tuder Three-Dimensional Reconstruction of Pulmonary Arteries in Plexiform Pulmonary Hypertension Using Cell-Specific Markers : Evidence for a Dynamic and Heterogeneous Process of PulmonaryEndothelial Cell Growth Am. J. Pathol., August 1, 1999; 155(2): 411 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. McLaughlin, D. E. Genthner, M. M. Panella, D. M. Hess, and S. Rich Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series Ann Intern Med, May 4, 1999; 130(9): 740 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Y Mok, H F Tse, and C S Lau Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost Lupus, May 1, 1999; 8(4): 328 - 331. [Abstract] [PDF]
|
|
|
|
|
|
A. P. Fishman Aminorex to Fen/Phen : An Epidemic Foretold Circulation, January 12, 1999; 99(1): 156 - 161. [Full Text] [PDF]
|
|
|
|
|
|
J. X.-J. Yuan, A. M. Aldinger, M. Juhaszova, J. Wang, J. V. Conte Jr, S. P. Gaine, J. B. Orens, and L. J. Rubin Dysfunctional Voltage-Gated K+ Channels in Pulmonary Artery Smooth Muscle Cells of Patients With Primary Pulmonary Hypertension Circulation, October 6, 1998; 98(14): 1400 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. OKADA, M. L. BERNSTEIN, W. ZHANG, D. P. SCHUSTER, and M. D. BOTNEY Angiotensin-converting Enzyme Inhibition Delays Pulmonary Vascular Neointimal Formation Am. J. Respir. Crit. Care Med., September 1, 1998; 158(3): 939 - 950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Maloney, C. C. Silliman, D. R. Ambruso, J. Wang, R. M. Tuder, and N. F. Voelkel In vitro release of vascular endothelial growth factor during platelet aggregation Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H1054 - H1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. McLaughlin, D. E. Genthner, M. M. Panella, and S. Rich Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary Hypertension N. Engl. J. Med., January 29, 1998; 338(5): 273 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. WRIGHT, R. M. TUDER, J. WANG, C. D. COOL, R. A. LEPLEY, and N. F. VOELKEL 5-Lipoxygenase and 5-Lipoxygenase Activating Protein (FLAP) Immunoreactivity in Lungs from Patients with Primary Pulmonary Hypertension Am. J. Respir. Crit. Care Med., January 1, 1997; 157(1): 219 - 229. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. L. Pfister and W. B. Campbell Role of Endothelium-Derived Metabolites of Arachidonic Acid in Enhanced Pulmonary Artery Contractions in Female Rabbits Hypertension, January 1, 1996; 27(1): 43 - 48. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Alpert, M. D. Concannon, B. Mukerji, and V. Mukerji Pharmacotherapy of Chronic Pulmonary Arterial Hypertension: Value and Limitations: Part I: Primary Pulmonary Hypertension Angiology, August 1, 1994; 45(8): 667 - 676. [Abstract] [PDF]
|
|
|
|
|
|
G. M. Folger JR Pulmonary Vascular Disease in Children with Congenital Cardiovascular Malformations: Etiologic Considerations Angiology, December 1, 1983; 34(12): 784 - 811. [Abstract] [PDF]
|
|
|
|
|
|
E. Trell Primary and Chronic Thromboembolic Pulmonary Hypertension: Nosologic Spectrum Angiology, September 1, 1972; 23(9): 558 - 574. [PDF]
|
|
|
|
|
|
L. Liu and J. P. Sackler A Case of Pulmonary Veno-Occlusive Disease: Etiological and Therapeutic Appraisal Angiology, May 1, 1972; 23(5): 299 - 304. [PDF]
|
|